Pivot to partnerships

Since its last major human medicines acquisition eight years ago, Eli Lilly and Co. has pivoted away from large M&A deals in favor of partnerships in its core areas of cancer, neurology, diabetes and inflammation. The pharma is willing to work with potential partners for several years to demonstrate a commitment before a program is ever brought in house.

BioCentury recently spoke with Darren Carroll, who became SVP of corporate business development in January 2015. He was previously VP of corporate development...